Relationship of Helicobacter Pylori Eradication Therapy and Long-term Outcome in Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
MeSH terms: Acute Coronary Syndrome; Syndrome
Study type: Observational

Summary: 
      Objective: To investigate the relationship between Helicobacter pylori (Hp) infection and the
      prognosis of acute coronary syndrome (ACS) in a Chinese population and to explore the
      significance of Hp eradication therapy in preventing major adverse cardiac events (MACE) and
      upper gastrointestinal bleeding (UGIB) in patients on dual antiplatelet treatment. Methods:
      To analyze 472 ACS patients with drug-eluting stent (DES) implantation from January 1, 2008
      to December 31, 2010 in the department of cardiology at Beijing Mentougou District Hospital.
      Patients were divided into three groups: Group 1, the Hp-negative patients (Hp-); Group 2,
      the Hp-positive patients with eradication therapy (Hp+ Therapy); and Group 3, the Hp-positive
      patients without eradication therapy (Hp+ No Therapy). All patients took 13C urea breath
      test, high sensitive C-reactive protein (hs-CRP)，homocysteine (HCY) and other biochemical
      indicators. The investigators explored the correlations of Hp eradication therapy with MACE
      (including recurrent myocardial infarction, revascularization and death) and UGIB after 3 to
      5 years of follow-up using survival analysis.
    

Detailed description: 
      This study is a single-center and random analysis. The consecutive hospitalized patients with
      ACS at Beijing Mentougou District Hospital from January 1, 2008 to December 31, 2010 were
      enrolled. Figure 1 is a flow diagram of the trial. There were 259 males (54.9%) and 213
      females (45.1%) with an average age of 61.1 ± 11.0 years. Patient's history, physical
      examination, and laboratory results were recorded. All patients were divided into the
      Hp-negative group (Hp-, group 1.) and the Hp-positive group (Hp+). The Hp+ group were
      randomly divided into two groups: Group 2, the Hp+ with eradication therapy (Hp+ Therapy);
      and Group 3, the Hp+ without eradication therapy (Hp+No Therapy).
    

Observational model: Case-Control
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        This study is a single-center and random analysis. The consecutive hospitalized patients
        with ACS at Beijing Mentougou District Hospital from January 1, 2008 to December 31, 2010
        were enrolled. Figure 1 is a flow diagram of the trial. There were 259 males (54.9%) and
        213 females (45.1%) with an average age of 61.1 ± 11.0 years. Patient's history, physical
        examination, and laboratory results were recorded. All patients were divided into the
        Hp-negative group (Hp-, group 1.) and the Hp-positive group (Hp+). The Hp+ group were
        randomly divided into two groups: Group 2, the Hp+ with eradication therapy (Hp+ Therapy);
        and Group 3, the Hp+ without eradication therapy (Hp+No Therapy).
      
Keywords: helicobacter pylori; eradication therapy; major adverse cardiac events; long-term outcome; To explore the significance of Hp eradication therapy in preventing major adverse cardiac events (MACE) and upper gastrointestinal bleeding (UGIB).